• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25 filed by Enzo Biochem Inc.

    4/7/25 4:15:02 PM ET
    $ENZ
    Medical Specialities
    Health Care
    Get the next $ENZ alert in real time by email
    25 1 ea0237385-25_enzobiochem.htm FORM 25

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 25

     

     

     

    NOTIFICATION OF REMOVAL FROM LISTING

    AND/OR REGISTRATION UNDER SECTION 12(B)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Commission File Number 001-09974

     

    ENZO BIOCHEM, INC.

    THE NEW YORK STOCK EXCHANGE

    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

     

     

     

    21 Executive Blvd., Farmingdale, New York 11735

    (631) 755-5500

    (Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

     

    Common Stock, par value $0.01 per share (NYSE: ENZ)
    (Description of class of securities)

     

     

     

    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

     

    ☐ 17 CFR 240.12d2-2(a)(1)
       
    ☐ 17 CFR 240.12d2-2(a)(2)
       
    ☐ 17 CFR 240.12d2-2(a)(3)
       
    ☐ 17 CFR 240.12d2-2(a)(4)
       
    ☐ Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.
       
    ☒ Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

     

     

     

     

     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, Enzo Biochem, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

     

    April 7, 2025   By: Patricia Eckert   Chief Financial Officer
    Date   Name   Title

     

     

     

     

     

    Get the next $ENZ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ENZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ENZ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction

      Forms Special Committee of the Board to Lead Evaluation of Viable Options for Maximizing Shareholder Value Engages Independent Financial and Legal Advisors to Support Thorough Process Remains Committed to Maintaining Focus on Cost Containment, Cash Preservation and Near-Term Initiatives to Enhance Value Farmingdale, NY, April 22, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (OTCQX:ENZB) ("Enzo" or the "Company") today announced that its Board of Directors (the "Board") has commenced a review of strategic alternatives after recently receiving multiple inquiries regarding a potential transaction with the Company. In connection with this process, the Board has formed a special committee of

      4/22/25 8:30:00 AM ET
      $ENZ
      Medical Specialities
      Health Care
    • Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX

      FARMINGDALE, N.Y., March 28, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced its intention to voluntarily delist its common stock from The New York Stock Exchange ("NYSE") and to have its common stock quoted on the OTCQX Best Market ("OTCQX"). Enzo provided notice of the voluntary delisting to the NYSE on March 28, 2025 and intends to timely file a notification of removal from listing on Form 25 with the Securities and Exchange Commission (the "SEC") to effect the delisting.  It is anticipated that the delisting will become effective on or about April 17, 2025, with trading on OTCQX to commence on or about April 18, 2025. This announceme

      3/28/25 4:15:00 PM ET
      $ENZ
      Medical Specialities
      Health Care
    • Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results

      FARMINGDALE, N.Y., March 17, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced financial results for the fiscal second quarter ended January 31, 2025, with sequential quarter improvement in revenue, gross margin and operating profit / loss. Financial Highlights The Company's second-quarter gross margin percentage of 52% increased sequentially from 37% during Q1 2025 and increased from 49% during the second quarter of the prior year. These improvements were driven by change in revenues, cost efficiency actions completed, and mix of products sold.The Enzo Life Sciences Products segment, which excludes discontinued operations and Corporate over

      3/17/25 4:20:42 PM ET
      $ENZ
      Medical Specialities
      Health Care

    $ENZ
    Financials

    Live finance-specific insights

    See more
    • Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update

      FARMINGDALE, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced financial results for the fiscal first quarter ended October 31, 2024. First Quarter Highlights Enzo ended the first quarter with aggregate cash and cash equivalents of $47.7 million. The net cash used in operating activities during the first quarter decreased by $4.4 million compared to the prior year. The Company's first-quarter revenue of $6.2 million declined year-over-year by 20% due to declining market demand related to general continued headwinds in the life sciences tools space. Recent Events The declared special cash dividend of $0.10 per share on its

      12/16/24 4:17:15 PM ET
      $ENZ
      Medical Specialities
      Health Care
    • Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend

      FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had authorized a cash dividend of $0.10 per share of its common stock. Full Year Highlights The Company's revenues in the 2024 period of $31.9 million improved year-over-year by 3%. Enzo's sales to its industrial customers, which includes biotech and pharmaceutical companies, increased 46% driven by our drug development and cell and gene therapy focus.The Company's FY24 gross margin was 46%. The prio

      10/29/24 7:59:36 PM ET
      $ENZ
      Medical Specialities
      Health Care
    • The Radoff-Sudbury Group Files Definitive Proxy and Issues Letter to LifeVantage Corporation Stockholders

      Highlights the Destruction of 70% in Stockholder Value Under Garry Mauro's 10-Year Reign as Chairman Notes the Radoff-Sudbury Group's Aligned and Highly Qualified Director Candidates Collectively Own Significantly More Stock than the Entire LifeVantage Board and are Committed to Acting in Stockholders' Best Interests Urges Stockholders to Vote for the Radoff-Sudbury Group's Director Candidates – Dayton Judd, Michael Lohner and Bradley L. Radoff – on the BLUE Proxy Card Ahead of LifeVantage's Upcoming Annual Meeting Bradley L. Radoff and Sudbury Capital Fund, LP (together with their affiliates, the "Radoff-Sudbury Group" or "we"), who collectively own approximately 12.8% of the outstan

      9/26/23 8:00:00 AM ET
      $DSAQ
      $ENZ
      $FARM
      $FTLF
      Blank Checks
      Finance
      Medical Specialities
      Health Care

    $ENZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Enzo Biochem Inc. (Amendment)

      SC 13G/A - ENZO BIOCHEM INC (0000316253) (Subject)

      2/14/24 10:23:21 AM ET
      $ENZ
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Enzo Biochem Inc. (Amendment)

      SC 13G/A - ENZO BIOCHEM INC (0000316253) (Subject)

      2/13/24 9:35:39 AM ET
      $ENZ
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Enzo Biochem Inc.

      SC 13G - ENZO BIOCHEM INC (0000316253) (Subject)

      9/11/23 5:14:43 PM ET
      $ENZ
      Medical Specialities
      Health Care

    $ENZ
    SEC Filings

    See more

    $ENZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Enzo Biochem Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - ENZO BIOCHEM INC (0000316253) (Filer)

      4/22/25 8:42:26 AM ET
      $ENZ
      Medical Specialities
      Health Care
    • Enzo Biochem Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - ENZO BIOCHEM INC (0000316253) (Filer)

      4/21/25 9:15:01 AM ET
      $ENZ
      Medical Specialities
      Health Care
    • SEC Form 25 filed by Enzo Biochem Inc.

      25 - ENZO BIOCHEM INC (0000316253) (Filer)

      4/7/25 4:15:02 PM ET
      $ENZ
      Medical Specialities
      Health Care
    • Director Radoff Bradley Louis was granted 142,897 shares, increasing direct ownership by 3% to 4,533,779 units (SEC Form 4)

      4 - ENZO BIOCHEM INC (0000316253) (Issuer)

      1/17/25 4:44:45 PM ET
      $ENZ
      Medical Specialities
      Health Care
    • Director Pully Steven J was granted 142,897 shares, increasing direct ownership by 147% to 239,992 units (SEC Form 4)

      4 - ENZO BIOCHEM INC (0000316253) (Issuer)

      1/17/25 4:44:26 PM ET
      $ENZ
      Medical Specialities
      Health Care
    • Director Couchman Jonathan was granted 142,897 shares (SEC Form 4)

      4 - ENZO BIOCHEM INC (0000316253) (Issuer)

      1/17/25 4:44:06 PM ET
      $ENZ
      Medical Specialities
      Health Care

    $ENZ
    Leadership Updates

    Live Leadership Updates

    See more
    • Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments

      FARMINGDALE, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company"), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments. Summary of the Fiscal Year 2023 Annual Shareholder Meeting Proposals Proposal One – The shareholders elected Kara Cannon, Steven J. Pully, Bradley L. Radoff, and Mary Tagliaferri, M.D. to the Company's Board of Directors to hold office for a term ending as of our Fiscal 2024 annual meeting of shareholders, and until each such director's successor is elected and qualified. Proposal Two – The shareholders did not approve, by a non

      2/1/24 8:30:00 AM ET
      $ENZ
      Medical Specialities
      Health Care
    • Enzo Biochem Announces Departure of Hamid Erfanian and Appointment of Kara Cannon as Interim CEO

      FARMINGDALE, NY, Sept. 06, 2023 (GLOBE NEWSWIRE) --  Enzo Biochem, Inc. (NYSE:ENZ) announced today that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with Enzo's Chief Operating Officer, Kara Cannon, assuming the role of interim CEO. "We thank Hamid for the commitment he has brought to Enzo Biochem, Inc."  Chairperson of the Board Mary Tagliaferri, MD stated, "Hamid successfully led the Company through the divestiture of Enzo Clinical Lab, Inc.  We wish him well in all his future endeavors and are excited to focus on the life sciences division. We are confident in Kara to lead th

      9/6/23 8:30:00 AM ET
      $ENZ
      Medical Specialities
      Health Care
    • Enzo Biochem, Inc. Appoints Patricia Eckert, CPA as Interim CFO

      NEW YORK, NY, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company"), a leading biosciences and diagnostics company, today announced the appointment of Patricia Eckert, CPA, as interim Chief Financial Officer (CFO).  Ms. Eckert's appointment follows the resignation of David Bench, who is departing the Company effective November 14, 2022 to pursue a new opportunity. "While bittersweet in light of David's departure, we are exceedingly pleased to have Patricia in position to advance into the position of interim CFO," remarked Hamid Erfanian, CEO of Enzo. "Patricia is exceptionally qualified given her years of experience and comprehensive knowledge of Enzo'

      10/20/22 8:15:00 AM ET
      $ENZ
      Medical Specialities
      Health Care